» Articles » PMID: 19732293

Signalling Pathway Alterations in Pituitary Adenomas: Involvement of Gsalpha, CAMP and Mitogen-activated Protein Kinases

Overview
Specialty Endocrinology
Date 2009 Sep 8
PMID 19732293
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Despite extensive research on sporadic pituitary adenomas, it is not yet possible to assign one protein alteration to one specific type of pituitary adenomas. Nevertheless, alterations of the cAMP pathway appear to be molecular hallmarks of most growth hormone (GH)-secreting adenomas. However, these alterations do not confer specific phenotypes to patients carrying these alterations. In this review, we summarise the literature regarding signalling alterations observed in GH-secreting adenomas. We focus on Gsalpha alterations and their possible cross-talk with the extracellular signal-related kinase (ERK)1/2 pathway. In the light of results obtained on human somatotroph adenoma cells in primary culture and on models of murine somatotroph cell lines, we postulate a crucial role for ERK1/2 in GH-secreting adenomas downstream of cAMP pathway alterations that might impact the tumoural phenotype.

Citing Articles

Pituitary Tumorigenesis-Implications for Management.

Vamvoukaki R, Chrysoulaki M, Betsi G, Xekouki P Medicina (Kaunas). 2023; 59(4).

PMID: 37109772 PMC: 10145673. DOI: 10.3390/medicina59040812.


Autoantibodies involved in primary and secondary adrenal insufficiency following treatment with immune checkpoint inhibitors.

Helderman N, Lucas M, Blank C Immunooncol Technol. 2023; 17:100374.

PMID: 36937704 PMC: 10014276. DOI: 10.1016/j.iotech.2023.100374.


Checkpoint inhibitor immune-related adverse events: A focused review on autoantibodies and B cells as biomarkers, advancements and future possibilities.

Taylor J, Gandhi A, Gray E, Zaenker P Front Immunol. 2023; 13:991433.

PMID: 36713389 PMC: 9874109. DOI: 10.3389/fimmu.2022.991433.


cAMP Signalling Pathway in Biocontrol Fungi.

Sun Z, Yu S, Wang C, Wang L Curr Issues Mol Biol. 2022; 44(6):2622-2634.

PMID: 35735620 PMC: 9221721. DOI: 10.3390/cimb44060179.


Somatotroph Tumors and the Epigenetic Status of the Locus.

Romanet P, Galluso J, Kamenicky P, Hage M, Theodoropoulou M, Roche C Int J Mol Sci. 2021; 22(14).

PMID: 34299200 PMC: 8306130. DOI: 10.3390/ijms22147570.